In order to ensure 2023 billing, testing must be activated before the end of the year, or within 30 days of proband sample collection (if sample was collected in 2023). For Exome, Genome, or Xpanded testing, if you do not expect parental samples to be received in time for testing to be activated with 2023 billing, please contact us at firstname.lastname@example.org to determine how to proceed.
GeneDx contributes to a wide range of studies and research initiatives. Our team collaborates with top researchers, clinicians and institutions to further progress the field of genetics and genomics.
Acute myeloid leukemia (AML) is the most common type of leukemia with a 5-year survival of 24%. Sema4 researchers, in partnership with Chungnam National University College of Medicine, South Korea and the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, have discovered that an estrogen-related receptor (ERRα) plays an role in AML development. These findings present ERRα as a new therapeutic target for drug development with potential to improve treatment response for blood cancers.
This study focuses on mitochondrial disease phenotypes and genotypes in infants who have undergone rapid DNA sequencing. As more NICUs are utilizing this technology, it remains an open question if one should also include rapid mitochondrial DNA (mt-DNA) testing. This study evaluates the incidence of mitochondrial disease caused by both n-DNA and mt-DNA in NICU patients.
This large study of 404 individuals with CTNNB1 variants provides a more comprehensive understanding of CTNNB1-related phenotypes and related health needs, and confirms that cerebral palsy (CP) is a common feature amongst individuals with CTNNB1 variants.
Among patients with cerebral palsy who underwent exome sequencing, the prevalence of pathogenic and likely pathogenic variants was 32.7% in a cohort that predominantly consisted of pediatric patients and 10.5% in a cohort that predominantly consisted of adult patients.
Multiple lines of independent evidence to show that different variant types in a single gene, SATB1, cause clinically overlapping but distinct neurodevelopmental disorders.
CDK19 de novo missense variants are responsible for a novel neurodevelopmental disorder.
Trio exome sequencing (ES) presents a comprehensive method for detection of UPD alongside sequence and copy-number variant analysis.
GNAI1-related NDD is most often characterized by severe to profound delays, hypotonia, epilepsy that ranges from self-limiting to intractable, behavior problems, and variable mild dysmorphic features.
The delineation of disease entities is complex, yet recent advances in the molecular characterization of diseases provide opportunities to designate diseases in a biologically valid manner. Here, we have formalized an approach to the delineation of Mendelian genetic disorders.
We expand the spectrum of disorders associated with pathogenic variants in POLR3B to include a de novo heterozygous POLR3B-related disorder.
Further delineation of the molecular spectrum of PIGS-related disorders would improve management, help develop treatments, and encourage the expansion of diagnostic genetic testing to include this gene as a potential cause of neurodevelopmental disorders and epilepsy.
This GeneDx co-authored review provides education to the clinical pathology field on the practice of sequence variant interpretation. In addition to describing the evidence types currently utilized in variant interpretation, the authors also review the history of this practice and highlight future directions the field may take.